| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 4.6 | 5.0 |
| Profit before tax | 1.0 | -1.6 |
| Net income | 1.0 | -1.6 |
| EPS (diluted, $ a share) | $-0.00 | $-0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -6.5% |
|---|---|
| Operating margin | 16.0% |
10-Q filed with the SEC, OTC: EVFM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Evofem Biosciences, Inc.: key numbers
- Share price
- $0.0060Close, Nov 13
- Market cap
- $795K
- Shares outstanding
- 132.53MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Evofem Biosciences, Inc.
All →Evofem Biosciences Financial Results
Evofem Biosciences reported Q3 2026 financial results, achieving $0.7 million in operating income despite a slight decline in net sales to $4.6 million. The company highlighted the shipment of its 500,000th box of PHEXX and the addition of a fifth study site for an NIH-funded Phase 4 trial of SOLOSEC.
- Term
- Q3 2026
“While third quarter net sales reflect the cumulative impact of operating without dedicated growth capital for brand promotion and physician outreach since late 2022, we are proud of the discipline, efficiency and tenacity demonstrated across the organization. Through rigorous expense management, we generated $0.7 million of operating income during the quarter while continuing to support patients and healthcare providers who rely on our innovative sexual health products.”
Saundra Pelletier, CEO of Evofem
Evofem Biosciences Debt Financing Update with Adjuvant Global Health Technology Fund, L.P.
Evofem Biosciences entered into a fifth amendment to its Securities Purchase Agreement with Adjuvant Global Health Technology Fund. The amendment extends the maturity date of outstanding convertible promissory notes to December 1, 2026, and removes certain affirmative covenants.
- Counterparty
- Adjuvant Global Health Technology Fund, L.P.
- Term
- through Dec 2026
Evofem Biosciences Capacity Expansion
Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical Limited to establish a second production source for its contraceptive gel, PHEXX. The expansion is designed to enhance supply chain flexibility and is expected to reduce unit costs by 40% or more once regulatory approval for the new facility is obtained.
- Counterparty
- Zhaoke Ophthalmology Pharmaceutical Limited